{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-010589","form_type":"8-K","ticker":"COYA","cik":"0001835022","company_name":"Coya Therapeutics, Inc.","filed_at":"2023-03-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.952588+00:00","generated_at":"2026-06-17T10:59:44.981962+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Coya Therapeutics reports FY2022 net loss of $12.2M; positive ALS data for COYA 302","bullets":["Net loss of $12.2M for FY2022 vs $4.9M in FY2021; R&D expense rose to $4.4M from $2.5M.","Cash and cash equivalents $5.9M at Dec 31, 2022; IPO net proceeds of $14.5M received in Jan 2023.","Positive proof-of-concept data for COYA 302 in ALS: halted disease progression over 6 months in 4 patients.","Entered worldwide agreement with Dr. Reddy's to in-license abatacept biosimilar and out-license COYA 301.","Anticipates IND filing for COYA 301 in FTD and COYA 302 in neurodegenerative diseases in H2 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-010589","json":"https://secwatch.observer/filing/0000950170-23-010589.json","markdown":"https://secwatch.observer/filing/0000950170-23-010589.md","text":"https://secwatch.observer/filing/0000950170-23-010589.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1835022/000095017023010589/0000950170-23-010589-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1835022/000095017023010589/coya-20230329.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T10:59:44.981962+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f4a76f0388e335a3ac29370ebf609d66e5a2a8e3","claim":"Coya Therapeutics, Inc. reported fiscal year ended December 31, 2022 results: net income $12.2 million.","evidence_excerpt":"On March 29, 2023, Coya Therapeutics, Inc. (the “Company”) issued a press release disclosing certain information regarding its results of operations for the fiscal year ended December 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1835022/000095017023010589/0000950170-23-010589-index.htm","confidence":0.7,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fiscal year ended December 31, 2022"},{"label":"Net income","value":"$12.2 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}